Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3579 - Time to surgery in early breast cancer treated with neoadjuvant chemotherapy

Date

11 Sep 2017

Session

Poster display session

Topics

Surgical Oncology;  Radiation Oncology;  Breast Cancer

Presenters

Marika Cinausero

Citation

Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362

Authors

M. Cinausero1, G. Galli2, D. Basile1, L. Gerratana1, G. Fasola1, F. De Braud3, M. Sant4, B. Paolini5, S. Di Cosimo6, F. Puglisi1

Author affiliations

  • 1 Department Of Oncology, University Hospital of Udine, 33100 - Udine/IT
  • 2 Division Of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 3 Department Of Oncology, University of Milan, Milan/IT
  • 4 Analytic Epidemiology And Health Impact Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 5 Department Of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
  • 6 Biomarker Unit, Dipartimento Di Ricerca Applicata E Sviluppo Tecnologico (drast), Fondazione IRCCS Istituto Nazionale dei Tumori, Milan/IT
More

Resources

Abstract 3579

Background

A delay between surgery and adjuvant chemotherapy (CT) has been associated with worse outcome in early breast cancer (BC), but little is known about timing-related consequences in the neoadjuvant setting. Aim of this study is to investigate the impact of the interval between the end of neoadjuvant CT and surgery (CTTS).

Methods

This retrospective study analyzed a series of 469 consecutive BC patients (pts) receiving neoadjuvant CT at the Department of Oncology of Udine (n = 222) and of the Istituto Nazionale Tumori of Milan (n = 247), between 2004 and 2015. CTTS was defined as the time between the last CT administration and surgery. Prognostic impact was investigated through Cox regression.

Results

Luminal-like subtype was the most frequent (53.69%) followed by HER2-positive (29.26%) and triple negative BC (17.05%). Median follow-up was 55.07 months (mo). Estimated overall survival (OS) at 24 and 60 mo was 96.4% and 88.2%, respectively. Estimated relapse free survival (RFS) at 24 and 60 mo was 83.6% and 65.8%. Median CTTS was 1.08 mo (25%-75% range: 0.89 - 1.2 mo). Among the total population no statistically significant differences were observed in terms of OS and RFS between CTTS > 1 vs  =20% were associated with worse RFS (HR 2.09, 95%CI 1.31-3.33; HR 2.77, 95%CI 1.30-5.91, respectively); on the other hand, a pathological complete response was associated with better RFS (HR 0.23, 95%CI 0.09-0.56). In terms of OS, grading and Ki67 were marginally significant. Subgroup analysis for CTTS showed no statistically significant differences when stratification for the main clinico-pathological features was applied. Notably, a trend for interaction in the nodal status stratification was observed.

Conclusions

This study explored the impact on RFS and OS of the interval between the end of neaodjuvant CT and surgery. Notwithstanding the exploratory purpose, the results suggest that an interval superior to 1 month was not significantly detrimental in terms of both RFS and OS.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.